Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Ear-canal lavage for curing noninvasive otomycosis: A randomized controlled trial.
Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveFungal infection of the external auditory canal, otomycosis, is generally a superficial, but sometimes stubborn mycotic infection that rarely involves the middle ear. We designed a randomized, controlled cohort study to analyse the treatment effect of ear canal lavage on otomycosis.
methodsThe clinical patients were divided into two groups: an irrigation group and an irrigation + local drug treatment control group. The patients were followed up once a month for three months.
resultsFrom January 2022 to December 2023, a total of 102 patients treated for otomycosis were enrolled, and 98 of the patients were followed up for three months. 22 of the 98 patients (22.45%) had no or minor symptoms. Common symptoms such as pruritus, pain, hearing impairment, etc., presented solely or in combination. Our fungal culture results revealed that, in 83 patients (84.69%), the otomycotic pathogen was Aspergillus, in 3 patients (3.06%) it was Penicillium, in 2 patients (2.04%) it was Candida species, and in the remaining 13 patients (13.27%) it was negative. There were 3 patients (3.06%) with a mixture of fungal culture reports. In the lavage group, 48 (48/52, 92.30%) patients were cured with initial treatment after three months of follow-up, two (2/52, 3.85%) patients were cured after one month but were lost to follow-up after three months, and two (2/52, 3.85%) patients failed after initial treatment, received topical miconazole ointment treatment and were eventually cured. In the irrigation + local drug control group, 48 (48/50, 96.00%) subjects responded to initial treatment without recurrent disease after three months; 2 (2/50, 4.00%) subjects were lost to follow-up. According to Fisher's exact test, there was no significant difference in treatment efficiency between the two groups (P = 0.258).
conclusionThis study demonstrated that the diagnosis of otomycosis requires vigilance from clinicians given its nonspecific or minor symptoms. Both ear canal rinses and local antifungal creams are effective, and sequential treatment via both methods is reasonable.
Indexed as
Identifiers
40317309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.